H eart transplant (HT) has become a widely accepted treatment for end-stage heart failure in both children and adults. 1, 2 However, it is resource-intensive with reported median hospital charges of US $137679 in adults and mean hospital charges of greater than US $450000 in children. 3, 4 At least 1 prior report from patients transplanted between 1997 and 2006 suggests that hospital costs associated with pediatric HT have increased over time 3 ; however, there have been no publications describing resource utilization in this population from a more contemporary cohort. Additionally, many changes have occurred over time that may impact resource utilization, including shifts in the use of mechanical circulatory support (MCS) and increasing patient complexity.
Ventricular assist device (VAD) use in children has increased significantly over the past 10 years, 5 likely impacting the costs associated with HT. Mahle et al 6 reported mean hospital costs of US $758199 for pediatric patients bridged to HT with a VAD between 2002 and 2007. Waitlist survival has also improved over time, 7 likely resulting in increased waitlist duration and associated costs. In addition, recent changes in pediatric heart allocation that prioritize donor hearts to the most critically ill candidates, including those with congenital heart disease and those who require VAD support, are likely to further impact waitlist durations and contribute to increases in the costs associated with pediatric HT. 8 This project aimed to describe the changes in hospitalization costs associated with pediatric HT over time. We hypothesized that improvements in waitlist survival and increases in the frequency of VAD utilization would result in increases in cost over time.
MATERIALS AND METHODS
This study used a unique database linkage between the Scientific Registry of Transplant Recipients (SRTR, Minneapolis Medical Research Foundation, Minneapolis, MN) and the Pediatric Health Information System (PHIS, Children's Hospital Association, Lenexa, KS) administrative database and has been previously described. 9 The SRTR data system includes data on all donors, waitlisted candidates, and transplant recipients in the United States, submitted by the members 9 The PHIS database is an administrative database that collects clinical and resource utilization data for hospital encounters from 49 tertiary care children's hospitals. This includes data from inpatient hospitalizations, observation, ambulatory surgery, and emergency department visits. This database accumulates encounter-level diagnosis and procedural ICD-9 and ICD-10 codes, payer information, along with daily encounter-level hospital charge data. 9 All pediatric (age < 21 years) patients (2002-2016) with available hospital charge information in the linked database were included. Hospital charges were converted to costs using hospital-specific and year-specific cost-to-charge ratios. All costs were adjusted for inflation to 2016 US dollars using the medical component of the Consumer Price Index. Costs were assessed for the entire transplant hospitalization, the pretransplant hospitalization period (day of admission to the day before HT), and for the post-HT period (day before HT to the day of discharge). Adjusted patient costs were calculated with generalized linear mixed effects models using an exponential distribution, and included a random hospital intercept. Variables included in the total and posttransplant cost models were selected a priori and included era, patient age, diagnosis (cardiomyopathy, congenital heart disease, or retransplant), race, the need for extracorporeal membrane oxygenation (ECMO) support pretransplant or posttransplant, VAD support, ventilator support, inotropic support, total length of stay, rejection before hospital discharge, and the need for dialysis posttransplant. The pretransplant cost model included the same variables but excluded those that were dependent on posttransplant events (posttransplant ECMO, total length of stay, rejection before hospital discharge, and the need for dialysis posttransplant). Adjusted costs were expressed as the least squares mean with 95% confidence intervals obtained from the generalized linear mixed models.
Included patients were divided into 3 eras: era 1 (2002-2006), era 2 (2007-2011), and era 3 (2012-2016). Patient demographics were compared across eras using standard summary statistics and either the chi squared or Kruskal-Wallis test, as appropriate. Hospitalization costs were compared across eras using generalized linear mixed effects models. Hospitalization costs were subdivided into categories including pharmacy, laboratory, imaging, supply, clinical, and other costs and the analysis was repeated. Other costs are comprised primarily of room (including operating room) and nursing costs. To assess the impact of VAD support on the changes in hospitalization costs over time, a separate generalized linear mixed effects model was generated to assess the changes in VAD costs across eras, adjusting for the same variables included in the original models. All statistical analyses were performed in SAS version 9.4 (SAS Institute; Unadjusted and adjusted hospitalization costs based on era Cary, NC) or STATA version 13 (StataCorp LLC; College Station, TX) with P < 0.05 considered statistically significant. This project was approved by the Vanderbilt University IRB, PHIS, and SRTR.
RESULTS
A total of 2896 patients were included in the study with 649 (22.4%) transplanted during era 1, 1028 (35.5%) transplanted during era 2, and 1219 (42.1%) transplanted during era 3. Patient characteristics by era are shown in Table 1 . Over time there has been a trend towards higher waitlist urgency status with 85.1% of patients listed UNOS status 1A at the time of HT in the 2 most recent eras compared to 74.4% of patients listed UNOS status 1A at HT in era 1 (P < 0.001). Fewer patients have been supported with ECMO at HT over time (9.1% vs 5.4% vs 3.6% across eras 1, 2, and 3 respectively, P < 0.001) and VAD use has increased over the same period (7.1% vs 17.1% vs 22.2%, P < 0.001). There has also been an increase in the use of inhaled nitric oxide after HT and a trend towards fewer patients requiring ventilator support at HT. Between era 1 and era 2, there was a significant increase in the total (41 days vs 52 days, P < 0.001) and pre-HT (16 days vs 24 days, P < 0.001) length of stay but a decrease in the number of days mechanical ventilation was used after HT (mean 16.9 days vs 9.7 days, P < 0.001). There has also been a decrease in the incidence of acute rejection before hospital discharge (18.4% vs 13.5%, P = 0.02) and an increased incidence of chylothorax (1.8% vs 6.2%, P < 0.001) between era 1 and era 2. There was no difference across eras based on patient age, diagnosis, sex, blood type, the need for pre-HT inotropic support, ICU length of stay, the incidence of stroke, and the need for post-HT dialysis or cardiac reoperation.
Adjusted total, pre-, and post-HT costs by era are shown in Table 2 . Between era 1 and era 2, there was no significant change in total or posttransplant hospitalization costs. Over the same period, there was a significant increase in pretransplant hospitalization costs (US $343692 vs US $435554; P < 0.001). In the most recent era, there was a decline in total (US $906 454 vs US $767221; P < 0.001), pretransplant (US $435554 vs US $353364; P < 0.001), and posttransplant (US $586133 vs US $508719; P = 0.002) hospitalization costs.
Total costs based on area of spending are shown in Figure 1 . Clinical and other costs represent the largest expenditures for the total hospitalization. The highest cost services in these groups include organ acquisition and procurement, organ transplant service, and intensive care unit charges. Between era 1 and era 2, there were no significant changes in total costs across any area of spending (ie, pharmacy, laboratory, imaging, supply, clinical, and other costs). Between era 2 and era 3, there were significant decreases in total laboratory, supply, and other costs and a trend towards decreased total pharmacy and clinical costs. Imaging costs did not change during this timeframe.
Changes in VAD costs over time are shown in Table 3 . There was a trend toward decreasing total hospitalization cost for patients supported with a VAD across eras. 
DISCUSSION
Our analysis demonstrates that, although pre-HT hospitalization costs increased between era 1 and era 2, overall costs have decreased in the most recent era. These improvements were seen during all periods of the transplant hospitalization, including total, pretransplant, and posttransplant care. These findings suggest the evolution of more costeffective management strategies, potentially impacted by advances in pediatric MCS.
The early increases seen in pre-HT costs are likely multifactorial; however, shifts in pediatric MCS strategies may play a critical role. VAD use in children has increased significantly over the past 10 years. 5 We also observed this change with VAD use increasing from 7.1% of patients to 22.2% of patients over the 15-year timeframe included in this study. Concurrently, there has been a decline in the use of ECMO for patients undergoing HT. Although this shift in MCS strategy may contribute to increases in pre-HT costs, the superior outcomes of VAD support compared with ECMO 10 may offset this added cost. In fact, our analysis demonstrates that the costs associated with HT have decreased in the most recent era. It is possible that the shift in MCS strategy from ECMO to VAD has resulted in patients being better supported before HT and leading to a less complicated pre-and post-HT course. Any cost savings associated with VAD support may be outweighed by increased utilization over time. Prior studies have demonstrated that as experience with VAD support increases, costs decrease. 11 We hypothesize that the costs associated with VAD support may be declining as centers gain more experience in successful candidate selection, device management, detection of device complications, and as the use of continuous flow devices expand further in the pediatric population. In fact, our analysis suggests that the total hospitalization costs for VAD supported patients may be decreasing over time. It is also important to note that with each successive era, pediatric HT outcomes have improved. 2 This improvement in early mortality may also influence hospitalization costs over time as early mortality may decrease costs.
The early increase in pre-HT costs may also be impacted by waitlist times. Survival on the waitlist has improved in the recent era, 7 which may be directly related to the increased availability of VADs, allowing a longer duration of support. Although this likely represents overall improvement in management strategies, this also leads to longer waitlist times and the potential for higher acuity patients undergoing HT. Both of these factors may result in increased costs.
There are limited prior studies addressing the costs associated with pediatric HT and only one that addressed the changes in costs over time. Law et al 3 reported a 160% increase in hospital charges associated with pediatric HT from 1997 to 2006. Our analysis provides more contemporary cost data compared to this prior study, and represents the largest reported US cohort to date. Importantly, although our analysis confirms an increase in pre-HT costs in earlier eras, data from the most recent era suggest the evolution of more cost effective management strategies.
These data demonstrate that areas of cost expenditure have also changed over time. Cost improvements were seen in laboratory, supply, and other costs, whereas no significant decreases in cost were observed in pharmacy, imaging, and clinical costs. Any potential cost saving strategies for pharmacy and imaging costs may be outweighed by other factors. Unadjusted and adjusted hospitalization costs based on VAD utilization Pharmacy costs may be influenced by increases in medication costs as well as changes in medication prescribing patterns over time. There has been a shift toward greater utilization of tacrolimus and mycophenolate mofetil over time with fewer patients receiving cyclosporine, azathioprine, or steroids. 2, 12 Tacrolimus and mycophenolate mofetil have increased drug acquisition costs compared with cyclosporine and azathioprine respectively, but prior studies indicate that these agents are more cost-effective secondary to improved patient outcomes. [13] [14] [15] Additionally, there has been an increase in the use of induction therapy, further impacting pharmacy costs. 2, 12 In fact, T cell-depleting agents are now the most commonly used induction agents after pediatric HT and also represent the most costly alternative compared to IL-2 receptor antagonists or no induction therapy. 15 Additionally, multiple studies have documented a significant increase in the utilization of imaging over time, 16, 17 which may offset any potential cost savings in this area.
Prior studies have suggested that physicians have little awareness of the costs associated with the therapies they prescribe. [18] [19] [20] For this reason, any improvement in costs over time may not be related to physicians becoming more cost conscious, but instead related to improvements in patient management and quality of care. Further improvements in costs may be possible; however, these will likely require increased physician awareness and involvement in selecting the most cost-effective therapies.
LIMITATIONS
Our analysis has inherent limitations. Given the expected positive skewed distribution of cost data, 21 outliers may exist that overestimate the true cost. However, the use of generalized linear mixed effects models with an exponential distribution (to model skewed data) and reporting of least squares means represents the most statistically appropriate methodology. The linked PHIS and SRTR database only includes transplanted patients and therefore excludes patients who were listed but not transplanted. This may result in underestimation of costs, but is unlikely to significantly impact assessment of the changes in cost over time. Patients who were not hospitalized at the time of HT had negligible pre-HT costs, potentially resulting in underestimation of these costs. Additionally, we are only able to report data from hospitals that contribute to both databases. Although this unique linkage has allowed an in-depth assessment of HT costs over time, the etiology for the changes remains unclear. There may be significant regional variation in costs, potentially impacting our analysis. To address this, a study investigating the differences in costs across HT centers is underway. As with any large data set, there is the potential for missing or erroneous data. However, we believe that the merger of these 2 databases increases data granularity and helps to minimize this limitation.
CONCLUSION
The costs associated with pediatric HT have decreased in the most recent era, suggesting the evolution of more cost effective management strategies. These changes may be in part related to shifts in pediatric MCS.
